vaccheminf
project
aim
assess
efficaci
recommend
vaccin
adult
patient
undergo
autolog
allogen
hsct
challeng
antibodi
titr
refer
method
panel
immun
function
assay
measur
differ
time
point
cellular
immun
respons
standardis
antigen
vaccin
hypothesi
mani
pretranspl
posttranspl
factor
involv
vaccin
respons
may
alter
durabl
hsct
consequ
panel
immun
function
assay
may
best
predict
vaccin
efficaci
individu
level
assign
two
object
vaccheminf
project
assess
efficaci
five
major
vaccin
pneumococcu
hepat
b
viru
hbv
haemophilu
influenza
type
b
tetanu
diphtheria
administr
hsct
use
antibodi
titr
refer
method
reallif
set
correl
multipl
variabl
relat
haematolog
characterist
treatment
manag
pattern
posttranspl
immun
recoveri
transplantrel
complic
evalu
innov
ex
vivo
immun
function
assay
test
biomark
aim
measur
vaccinespecif
respons
part
vaccheminf
project
name
immunitair
greff
de
cellul
souch
fight
assign
agenda
measur
sequenti
function
innat
adapt
immun
respons
five
vaccin
identifi
transplantrel
factor
associ
low
immunis
map
recipi
hsct
immunolog
scale
would
allow
predict
vaccin
efficaci
ultim
establish
personalis
standard
care
vaccin
base
recipi
immun
recoveri
record
vaccheminf
project
singlecentr
prospect
consecut
cohort
adult
hsct
recipi
transplant
haematolog
depart
tertiarycar
univers
hospit
lyon
franc
past
year
haematolog
depart
carri
averag
rang
rang
autolog
allogen
hsct
yearli
respect
refer
haematologist
agreement
elig
adult
autolog
allogen
hsct
recipi
refer
vaccin
centr
dedic
immunocompromis
patient
host
infecti
diseas
depart
lyon
univers
hospit
inclus
vaccheminf
cohort
recruit
period
month
recipi
overal
followup
cover
period
month
purpos
fight
control
healthi
volunt
enrol
test
immun
function
assay
healthi
volunt
recruit
among
donor
blood
bank
etabliss
du
sang
ef
lyon
accord
ef
standardis
procedur
blood
donat
inform
consent
obtain
healthi
donor
person
data
anonymis
time
blood
donat
prior
transfer
blood
research
laboratori
workflow
vaccheminf
cohort
describ
figur
recipi
age
year
includ
first
visit
explan
given
implement
vaccin
schedul
preblood
test
assess
postvaccin
assess
month
month
month
visit
monitor
vaccin
respons
toler
fight
immun
function
assay
perform
describ
workflow
present
figur
exclus
criteria
appli
case
posttranspl
relaps
haematolog
underli
diseas
case
recipi
death
address
object
mention
primari
endpoint
measur
vaccinespecif
antibodi
titr
express
vaccin
respons
percentag
respond
geometr
mean
titr
gmt
immedi
month
vaccin
secondari
endpoint
investig
immun
statu
month
vaccin
routin
immunomonitor
fight
new
immun
function
assay
thoroughli
document
vaccin
safeti
implement
exhaust
prospect
maintain
databas
includ
variabl
relat
endpoint
follow
data
exhaust
record
vaccheminfspecif
numer
clinic
record
folder
ecrf
demograph
comorbid
use
haematopoiet
cell
transplant
comorbid
haematolog
underli
condit
box
transplant
characterist
includ
diseas
statu
transplant
prior
transplant
condit
regimen
graft
cellular
donor
type
donor
hla
match
stem
cell
sourc
graftversushost
diseas
gvhd
prophylaxi
includ
posttranspl
cyclophosphamid
haploident
transplant
donor
recipi
serostatu
cytomegaloviru
epsteinbarr
viru
toxoplasmosi
box
posttranspl
characterist
includ
time
engraft
second
graft
appropri
occurr
grade
acut
gvhd
treatment
occurr
grade
chronic
gvhd
accord
last
nation
institut
health
consensu
criteria
opportunist
infect
bacteri
fungal
viral
parasit
origin
occur
condit
day
hsct
hsct
use
european
group
blood
marrow
transplant
classif
infect
infecti
agentrel
reactiv
diseas
updat
latest
guidelin
list
full
definit
criteria
provid
tabl
peripher
blood
tlymphocyt
blymphocyt
subset
natur
killer
count
box
event
variabl
correspond
appli
french
vaccin
schedul
tabl
respons
vaccin
defin
follow
pneumococcu
mgl
igg
titr
correspond
healthi
popul
rang
supplier
data
immunocompet
adult
vaccin
nonconjug
pneumococc
vaccin
median
increas
igg
titr
iqr
consequ
fourfold
increas
igg
titr
consid
signific
reach
immunis
h
influenza
type
b
serolog
definit
critic
valu
immunocompet
adult
vaccin
h
influenza
type
b
conjug
vaccin
median
increas
igg
titr
iqr
consensu
valu
consid
shortterm
protect
linear
limit
igg
titr
higher
standard
protect
threshold
consid
protect
tetanu
diphtheria
iuml
hbv
antihb
antibodi
titr
miuml
antihb
titr
iuml
consid
confer
longlast
box
pretranspl
variablesag
diabet
mellitustobacco
smoke
activestop
pack
per
year
chronic
pulmonari
diseasechron
heart
conditionchron
neurolog
conditionautoinflammatori
diseaseunderli
haematolog
diseasesacut
myeloid
leukaemiamyelodysplast
syndromeacut
lymphoblast
leukaemiamyeloprolif
neoplasmsacquir
bone
marrow
failur
syndromelymphoprolif
neoplasmsmultipl
myelomaantihla
antibodiespositivenegativedonor
specificsplenectomyfunct
hyposplenismhctci
haematopoiet
cell
transplant
comorbid
index
box
transplant
variablesdiseas
statu
transplantationearlyintermediateadvancedprior
transplant
gender
mismatchmal
recipi
femal
donorcondit
regimenmyeloablativereduc
intensitytot
bodi
irradi
yesno
dose
graft
cellularitytot
nucleat
cellsbon
marrowperipher
blood
cellskg
cord
blood
cellskg
cellsbon
marrowperipher
blood
cellskg
cord
blood
cellskg
cell
cellskg
abo
mismatchno
mismatchmajorminorbidirectionaldonor
hla
matchingmatch
siblingmatch
unrel
donormismatch
unrel
donorcord
blood
match
mismatch
haploidenticalstem
cell
sourcebon
marrowperipher
blood
mobilis
stem
cellscord
bloodgraftversushost
diseas
prophylaxisantithymocyt
globulinsciclosporintacrolimusmethotrexatemycophenol
mofetilcyclophosphamidemethylprednisolonedonor
recipi
serostatuscytomegalovirusepsteinbarr
virustoxoplasmosishepat
b
viru
investig
innat
adapt
immun
respons
two
standardis
immun
function
assay
carri
base
find
realism
project
establish
refer
interv
larg
cohort
healthi
briefli
first
immun
function
assay
consist
collect
whole
blood
sampl
use
standardis
trucultur
system
myriad
rbm
austin
texa
usa
directli
contain
immunogen
stimuli
medium
alon
null
lipopolysaccharid
lp
ngml
escherichia
coli
staphylococcu
aureu
enterotoxin
b
seb
stimul
supernat
pellet
collect
use
separ
valv
supernat
store
batch
serial
quantif
cytokin
tumour
necrosi
factor
alpha
interferon
gamma
simpl
plex
cartridg
proteinsimpl
san
jose
california
usa
use
ella
platform
proteinsimpl
cellular
pellet
stabilis
ml
trizol
ls
sigma
aldrich
saint
loui
missouri
usa
messeng
rna
mrna
isol
nucleosp
rna
tissu
kit
machereynagel
germani
analysi
mrna
express
use
ncounter
technolog
nanostr
technolog
seattl
washington
usa
consist
rna
hybridis
method
whose
gene
set
includ
second
immun
function
assay
consist
induc
tlymphocyt
prolifer
measur
releas
supernat
respons
ex
vivo
stimul
standard
mitogen
phytohaemagglutinin
pha
peripher
blood
mononuclear
cell
pbmc
isol
fresh
heparin
blood
sampl
ficol
densiti
gradient
centrifug
eurobio
le
uli
franc
incub
cultur
medium
overnight
pbmc
stimul
duplic
pha
remel
oxoid
thermo
fisher
scientif
usa
cell
cultur
plate
hour
incub
supernat
harvest
quantif
use
ella
platform
cell
harvest
cell
prolifer
determin
incorpor
deoxyuridin
edu
hour
tcell
use
clickit
edu
flow
kit
life
technolog
carlsbad
california
usa
first
cell
stain
allophycocyanin
apc
label
monoclon
antibodi
beckman
coulter
brea
california
usa
fix
iotest
fix
solut
beckman
coulter
edu
activ
reaction
cocktail
contain
alexa
fluor
azid
compon
clickit
flow
cytometri
analys
perform
navio
flow
cytomet
beckman
coulter
cell
first
select
among
total
event
base
monoparametr
histogram
percentag
edu
cell
among
cell
along
geometr
mean
fluoresc
intens
popul
measur
among
cell
use
immun
function
assay
describ
innov
approach
consist
test
altern
recal
antigen
varicella
zoster
viru
vzv
antigen
microbix
mississauga
ontario
canada
pneumococc
antigen
pfizer
franc
tetanu
toxoid
pasteur
institut
pari
franc
recal
antigen
stimul
perform
pbmc
quantifi
educel
measur
day
incub
whole
blood
sampl
hour
order
extract
rna
qiaamp
rna
blood
mini
kit
qiagen
franc
perform
revers
transcript
use
superscript
vilo
cdna
synthesi
kit
thermo
fisher
scientif
franc
gene
express
quantifi
qpcr
use
taqman
probe
thermo
fisher
scientif
cfx
connect
realtim
pcr
detect
system
biorad
hercul
california
usa
routin
cellular
immunophenotyp
process
haematolog
immunolog
laboratori
lyon
univers
hospit
lyonsud
edouard
herriot
hospit
respect
larg
panel
bcell
tcell
membran
marker
associ
memori
statu
investig
flow
cytometri
bcell
bcell
memori
bcell
commut
count
tcell
central
memori
tcell
effector
memori
tcell
count
addit
routin
subset
sera
venou
blood
collect
frozen
institut
de
agent
infectieux
croixrouss
hospit
lyon
univers
hospit
level
specif
serum
igg
seven
serotyp
includ
vaccin
marker
immun
respons
determin
use
commerci
elisa
vacczym
antipcp
igg
enzym
immunoassay
kit
bind
site
uk
addit
vzvspecif
igg
igm
laison
vzv
igg
igm
diasorin
itali
diphtheriaspecif
tetanusspecif
igg
vacczym
diphtheria
tetanu
toxoid
igg
enzym
immunoassay
kit
well
hbvspecif
antihb
antibodi
advia
xp
centaur
siemen
germani
titr
determin
biobank
viabl
pbmc
cryopreserv
requir
specif
written
consent
pbmc
sampl
store
centr
de
ressourc
biologiqu
lyonsud
hospit
lyon
univers
hospit
furthermor
fight
cohort
provid
opportun
establish
four
differ
type
biobank
enabl
explor
innov
biomark
trucultur
plasma
mrna
cellular
pellet
biobank
whole
blood
stimul
lp
seb
unstimul
studi
immun
respons
edta
plasma
biobank
studi
viral
reactiv
marker
solubl
host
biomark
rna
biobank
studi
new
transcriptom
host
biomark
rna
extract
whole
blood
collect
paxgen
blood
rna
tube
thermo
fischer
scientif
viabl
freez
pbmc
vaccheminf
project
focus
highli
specif
popul
patientsfor
vaccin
efficaci
data
avail
base
transplant
characterist
main
goal
studi
primarili
descript
preval
respond
differ
followup
time
sampl
size
requir
howev
take
account
preval
known
select
followup
time
logist
regress
model
use
base
calcul
machin
rule
thumb
suggest
inclus
patient
per
estim
paramet
reason
least
patient
requir
qualit
variabl
express
count
percentag
quantit
data
express
median
iqr
primari
endpoint
compar
well
regard
multipl
variabl
relat
haematolog
characterist
treatment
manag
pattern
posttranspl
immun
recoveri
transplantrel
complic
comparison
perform
use
wilcoxon
test
mannwhitney
u
test
test
fisher
exact
test
appropri
gmt
mean
ci
comput
transform
titr
transform
back
origin
unit
exponenti
vaccin
target
low
moder
respond
rate
associ
respondersnonrespond
endpoint
factor
establish
use
logist
regress
factor
associ
endpoint
signific
level
p
kept
multivari
logist
regress
model
model
adjust
two
three
confound
factor
chosen
accord
evidencebas
literatur
case
relaps
haematolog
diseas
case
death
followup
case
loss
followup
patient
includ
analysi
provid
least
prevaccin
one
postvaccin
assess
avail
analys
base
twosid
p
valu
statist
signific
defin
p
conduct
r
final
appropri
multipl
imput
ie
random
taken
consider
case
relev
amount
miss
valu
patient
involv
design
implement
studi
studi
particip
individu
inform
result
schedul
medic
visit
given
access
demand
final
public
studi
result
identif
recipi
includ
studi
kept
anonym
protect
cryptograph
code
data
anonym
extract
medic
record
hcl
softwar
inform
sign
consent
regist
computeris
record
recipi
full
inform
object
workflow
studi
given
possibl
provid
recipi
refus
particip
exit
studi
whenev
chosen
comprehens
notic
distribut
recipi
summaris
protocol
followup
studi
result
commun
scientif
meet
submit
public
peerreview
journal
interest
design
prospect
cohort
includ
consecut
adult
hsct
recipi
complet
vaccin
schedul
full
prevaccin
postvaccin
assess
independ
complic
immunomodulatori
therapi
test
schedul
reallif
set
anoth
interest
assess
antibodi
titr
month
vaccin
document
far
acknowledg
bias
contribut
overestim
serum
antibodi
concentr
first
heterogen
time
recipi
inclus
refer
refer
haematologist
signal
later
hsct
better
immun
recoveri
second
recipi
receiv
intraven
ig
transplant
may
overestim
assess
serolog
respons
vaccin
also
acknowledg
bia
due
serolog
method
notabl
pneumococcu
may
optimis
altern
method
measur
specif
antibodi
vitro
opsonis
test
purpos
immun
function
assay
measur
deeper
aspect
immun
respons
vaccin
precis
variabl
collect
databas
potenti
impact
immun
function
consequ
alter
readout
interpret
specif
sensit
assay
milieu
interieur
consortium
set
preliminari
refer
rang
healthi
immun
respons
natur
similarli
order
map
immun
disord
healthi
donor
vaccheminf
studi
provid
refer
panel
essenti
evalu
inrang
outrang
scale
addit
durat
followup
current
project
last
month
popul
patient
close
monitor
refer
physician
virtual
loss
followup
ad
valu
might
extend
durat
followup
year
recipi
agreement
sustain
qualiti
inform
nonetheless
acknowledg
potenti
confound
import
number
collect
variabl
sampl
size
may
allow
complex
analysi
may
like
statist
underpow
order
assess
impact
function
immun
statu
vaccin
respons
hsct
recipi
multicentr
studi
larger
number
patient
plan
futur
